Drug Discovery for Neurodegeneration

神经退行性疾病的药物发现

基本信息

批准号：
7332301
负责人：
Howard M. Fillit
金额：
$ 7.5万
依托单位：
ALZHEIMER'S DRUG DISCOVERY FOUNDATION
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-09-15 至 2008-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7332301
关键词：
Academia Academic Training Address Alzheimer&apos s Disease Amyotrophic Lateral Sclerosis Area Basic Science Biotechnology Budgets Comb animal structure Development Discipline Disease District of Columbia Drug Industry Education Foundations Goals Huntington Disease Incidence Industry Information Resources Institution Iron binding capacity measurement Journals Knowledge Lead Learning Minority Nerve Degeneration Neurodegenerative Disorders POMC gene Parkinson Disease Participant Peer Review Pharmaceutical Preparations Process Public Health Publishing Purpose Range Research Research Personnel Resources Scientist Services Students Therapeutic Intervention Time Training Translating United States National Institutes of Health Validation Woman Work concept cost day drug development drug discovery next generation novel therapeutics pre-clinical pre-clinical research prevent skills symposium

项目摘要

DESCRIPTION (provided by applicant): The Alzheimer's Drug Discovery Foundation's (ADDF) conference entitled Drug Discovery for Neurodegeneration will be held on February 4-5, 2008 in the Washington, DC area. The purpose of the conference is to advance drug discovery for neurodegenerative disease by training the next generation of scientific leaders on the process of translating basic research into novel therapeutic interventions. Formal education on this topic is needed because there is a documented knowledge gap in this area of research and there are very few opportunities outside the pharmaceutical industry for scientists to learn about these processes. The goals of the conference are consistent with the NIH's Roadmap: to bridge the knowledge gap in drug discovery and neurodegenerative disease; to bring together interdisciplinary scientists to stimulate new ways of combing skills and disciplines; to provide networking opportunities for these scientists to exchange ideas and resources; and to publish the proceedings in a peer-reviewed scientific journal. This two-day conference will give participants fundamental knowledge and resources on creating new drugs to treat and prevent neurodegenerative disease. It will also address the barriers and challenges associated with the following sub-topics: Target Identification & Validation; Lead Identification & Optimization; Lead Discovery; Pre-Clinical Proof-of-Concept & Development; Resources and Services for Advancing Drug Discovery; and Disease Specific Issues in Drug Discovery for Neurodegenerative Disease. Alzheimer's disease, Parkinson's disease, Huntington's disease, and Amyotrophic Lateral Sclerosis will be included in the discussions. Sessions will consist of 3 to 5 presentations with ample time for Q&A. With respect to the public-private partnership initiative of the Roadmap, ADDF will invite approximately 25 internationally recognized scientists, including women and minorities, from academia, the biotechnology and pharmaceutical industries, as well as the NIH, to serve as chairs or speakers. It is anticipated that this conference will serve an audience of 150 scientists from diverse backgrounds, of which 27% will be women, minorities, young/junior investigators, and graduate students. The public health problem ADDF seeks to solve is to reduce the incidence of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's disease and Amyotrophic Lateral Sclerosis. By offering this conference, ADDF will increase scientists' knowledge of the drug discovery processes and catalyze them to work together to develop commercially viable and effective disease modifying products. CTITIQUE 1: Objectives: Training of academic scientists in drug discovery, exchange of ideas, stimulate pre-clinical research, build public-private partnerships, publish proceedings, provide CME credits. 6 topics: targets, leads identification, lead optimization, pre-clinical POC, drug discovery resources, disease-specific issues. The confirmed and proposed speakers include senior and well recognized successful scientists in drug development from both industry and academics. Overall, the proposed conference would likely be quite useful to its targeted audience of academic investigators and would likely accomplish its goal of educating these investigators in drug development and would facilitate public-private partnerships. These activities would strengthen the quality of translational proposals submitted to the NIH. The four targeted disease areas of AD, PD, HD and ALS are quite appropriate for the neurodegenerative field. The focus of training academic scientists in the full range of drug discovery and development from target validation through IND work remains rare although IBC sponsors conferences that include some of these areas. It would be helpful to point out in more specific terms how the proposed conference compares to and is advantageous to these other conferences. The range and expertise of speakers could be broadened by decreasing some of the potential redundancy in which two or more speakers are from the same institution. The proportion of speakers who have actually made a direct and major contribution to the successful development of an approved drug should be increased. Budget: The overall budget is appropriate and the amount requested from NIA (less than half the total cost of the conference) is appropriate. Inclusion of women and minorities is appropriate.

描述（由申请人提供）：阿尔茨海默病药物发现基金会（ADDF）题为“神经退行性疾病药物发现”的会议将于 2008 年 2 月 4 日至 5 日在华盛顿特区举行。会议的目的是通过培训下一代科学领袖将基础研究转化为新型治疗干预措施来推进神经退行性疾病的药物发现。需要对此主题进行正式教育，因为该研究领域存在有记录的知识差距，并且在制药行业之外，科学家了解这些过程的机会很少。会议的目标与 NIH 的路线图一致：弥合药物发现和神经退行性疾病方面的知识差距；汇集跨学科科学家，激发结合技能和学科的新方法；为这些科学家提供交流想法和资源的交流机会；并在同行评审的科学期刊上发表会议记录。这次为期两天的会议将为与会者提供有关创造治疗和预防神经退行性疾病的新药的基础知识和资源。它还将解决与以下子主题相关的障碍和挑战：目标识别和验证；潜在客户识别和优化；领先发现；临床前概念验证和开发；促进药物发现的资源和服务；和神经退行性疾病药物发现中的疾病特定问题。阿尔茨海默病、帕金森病、亨廷顿病和肌萎缩侧索硬化症将纳入讨论范围。会议将包括 3 至 5 场演讲，并有充足的问答时间。关于路线图的公私合作倡议，ADDF将邀请来自学术界、生物技术和制药行业以及美国国立卫生研究院的大约25名国际知名科学家，包括女性和少数族裔科学家，担任主席或发言人。预计本次会议将为来自不同背景的 150 名科学家提供服务，其中 27% 为女性、少数族裔、年轻/初级研究人员和研究生。 ADDF 寻求解决的公共卫生问题是减少神经退行性疾病的发病率，例如阿尔茨海默病、帕金森病、亨廷顿病和肌萎缩侧索硬化症。通过举办这次会议，ADDF 将增加科学家对药物发现过程的了解，并促进他们共同努力开发商业上可行且有效的疾病缓解产品。 CTITIQUE 1：目标：在药物发现、交流思想、刺激临床前研究、建立公私伙伴关系、出版论文集、提供 CME 学分等方面对学术科学家进行培训。 6 个主题：靶标、先导化合物识别、先导化合物优化、临床前 POC、药物发现资源、疾病特定问题。已确认和提议的演讲者包括来自工业界和学术界的药物开发领域资深且公认的成功科学家。总体而言，拟议的会议可能对其学术研究人员的目标受众非常有用，并且可能会实现对这些研究人员进行药物开发教育的目标，并将促进公私伙伴关系。这些活动将提高提交给 NIH 的翻译提案的质量。 AD、PD、HD和ALS这四个目标疾病领域非常适合神经退行性疾病领域。尽管 IBC 赞助了包括其中一些领域的会议，但对学术科学家进行从靶点验证到 IND 工作的全方位药物发现和开发培训的关注仍然很少。如果能够更具体地指出拟议的会议与其他会议的比较和优势，将会有所帮助。通过减少来自同一机构的两个或更多演讲者的一些潜在冗余，可以扩大演讲者的范围和专业知识。应增加对批准药物的成功开发实际做出直接和重大贡献的演讲者比例。预算：总体预算合适，NIA要求的金额（不超过会议总费用的一半）合适。将妇女和少数族裔纳入其中是适当的。